Fu'an pharmaceutical industry 120 million investment fluorite ore into fluorine chemical industry

China Securities Network News (reporter Wang Yu) after abandoning the acquisition of Yunnan prescription Pharmaceutical, Fu'an medicine (300194, shares bar) and the focus on the fluorite ore field.　　23rd Evening Company announcement, its wholly-owned subsidiary of Yu Dang Pharmaceutical Co., Ltd. to Chongqing-Hyun Fluorite Mining Limited investment of 120 million yuan, for the development of the mining holding subsidiary Youyang County Yuen Liangshan Mining Company's fluorite Mineral resources, so as to enter the fluorine chemical industry. According to the bulletin, natural person Huang Hua owned 100% stake in the mining industry, and wholly-owned control of the round Liangshan mining. Qing Yu Tong used self-financing 120 million yuan to add to the mining industry, of which 6.4286 million of the registered capital, the remaining 113.5714 million into the capital, so that the registered capital of the mining industry from 15 million to 21.4286 million yuan, Huang Huang does not increase capital.　　After the negotiation, after the completion of the increase in capital, Qing Yu Dang will hold a 30% stake in the mining industry, Huanghua holds 70% stake. According to the assessment report, the mineral resources in the area of the round Liangshan mining region are 727,000 tons, the production capacity is 50,000 tons/year, and the evaluation value is about 353 million yuan.　　The capital increase will be mainly used for the construction of the Youyang County Xinglong Town Drum Dam Village Fluorite mine and the capital needed for its normal operation, and to improve the production capacity. As of June 30 this year, The total assets of the mining industry is 42.269 million yuan, the total liability is 27.7184 million yuan, net assets is 14.9506 million yuan, net profit-4.725 million yuan, the total assets of the round Liangshan mining is 9.1207 million yuan, the total liability is 7.6153 million yuan, net assets is 1.5055 million yuan, net profit-494,500 yuan.　　It is understood that the round Liangshan mining has begun to mining, because the original shareholders lack of funds, so the current production is still small, which is the cause of the losses. In addition, in order to ensure the investment rights and interests of Yu Dang, the parties also special agreement, in the increase in capital, Huang should be holding the 70% stake in the mining of the Qing Yu Tang.　　After making up the previous annual losses and extracting the Statutory Provident Fund, the mining industry should, in principle, allocate the distributed profits in full, and the proportion of Huang Huang and Qing Yu Dang is 60% and 40%. Among them, the profit distribution should first ensure that the profit distribution of Yu Dang is not less than 15 million yuan/year, if the income of the year is less than 15 million, the profits should be allocated to the Qing Yu Dang;　　, if the distribution of profits in the year is greater than 15 million yuan, should first to celebrate Yu Dang before the year less than 15 million yuan/year part of compensation, the remainder by the Huang and Qing Yu Dang in accordance with the proportion of 60% and 40% distribution.　　Huang also promised that the first three years after the completion of this increase in the mining industry, that is, from 2014 to 2016, the cumulative net profit of not less than 90 million yuan, of which 2014 shall not be less than 20 million yuan, otherwise, Qing Yu Dang has the right to demand its repurchase shares. Fu'an said that the implementation of the above measures will effectively reduceThe risk of this investment. Data show that fluorite is the main source of fluorine in industry, is the basic raw material of fluorine chemical industry, widely used in metallurgy, chemistry, building materials industry. In medicine, fluorine organic compounds can be used to manufacture fluorine-containing anticancer drugs, fluorine-containing pine, fluorine-carbon artificial blood, and other fluorine-containing drugs, including diazepam (such as fluoride), HIV protease inhibitors (such as Lanave), antibiotics (such as ofloxacin and norfloxacin) and narcotics (such as halothane) and so on.　　Fluorine-containing intermediates in fluorine fine chemicals also occupy an important position, the current domestic fluorine-containing intermediates to develop faster, in the global has a certain degree of influence. Fu'an pharmaceutical industry, said that the company's main products are antibiotics, in the research focus on products including anti-tumor, cardio-cerebral vascular drugs, its holding subsidiary of Guang ' An, Kate Pharmaceutical chemical Company is a production of pharmaceutical intermediates for the main business enterprise, with fluoride production technology and related pharmaceutical intermediates processing capacity, The company will be in the fluorine chemical products and related pharmaceutical areas of research and development, production, sales on the formation of industrial chain, to gain advantages.　　At the same time, through fluorite ore processing, sales and continuously improve the value-added products can also achieve good economic benefits, to promote the overall profitability of the company's promotion and rapid development. According to Fu'an pharmaceutical industry Chairman Wang Tian detailed introduction, fluorite in China is an important strategic resources, prohibit exports, in the industrial application prospects than "rare earths" is also precious. After the completion of the company's capital increase, the round Liangshan mining industry will rapidly expand the volume of production, market sales is not a problem. In the future, the mined fluorite mine will be used in three aspects: first, some of the original ore sales; the second is the development of Fu'an drug-related fluorine-containing drugs; third, cooperation with foreign manufacturers for deep processing. In his view, the future is most optimistic about the prospect of deep processing, "this will bring a very substantial benefit to the company."